Abstract: A transdermal delivery system for delivery of a triptan into a tissue membrane of a subject. The system includes a transdermal microporation apparatus for heating a skin surface and a triptan drug delivery patch. The drug delivery patch comprises a top layer comprising an adhesive, a middle layer comprising the triptan, and a bottom layer. A method for treating a subject comprises identifying a subject having a migraine, using the transdermal microporation apparatus to open a plurality of micropores in the skin of the subject, and applying the triptan drug delivery patch to the subject's skin over the micropores for a period of time effective to deliver the triptan through the micropores in an amount effective to treat the subject's migraine.

Abstract: A transdermal delivery system for delivery of a triptan into a tissue membrane of a subject. The system includes a transdermal microporation apparatus for heating a skin surface and a triptan drug delivery patch. The drug delivery patch comprises a top layer comprising an adhesive, a middle layer comprising the triptan, and a bottom layer. A method for treating a subject comprises identifying a subject having a migraine, using the transdermal microporation apparatus to open a plurality of micropores in the skin of the subject, and applying the triptan drug delivery patch to the subject's skin over the micropores for a period of time effective to deliver the triptan through the micropores in an amount effective to treat the subject's migraine.

Abstract: To provide a transdermal drug delivery patch that can be suitably used for an immediate release application of a pharmaceutical with a comparatively low molecular weight. A transdermal drug delivery patch, provided with a matrix and at least one drug disposed within the matrix, wherein the matrix has a water holding capacity of 10 mg/cm2 or less, and the drug is a pharmaceutical having a molecular weight of 5000 or less.

Abstract: Thin solid tablet compositions containing an active permeant can be used in methods for administering the permeant to a subject. The thin solid tablet can be incorporated into a patch. The patch can be used to administer the permeant, such as a drug and an excipient, to the subject by transdermal microporation.

Abstract: Systems and methods for controlling energy delivered for thermal ablation. An apparatus may include a conductive member comprising an array of conductive filaments, a power supply configured to provide the current to the conductive/resistive member in a plurality of electrical pulses, and a processing circuit coupled to the power supply. The processing circuit is configured to control the supply current value to be greater than or equal to a first current density and less than or equal to a second current density, and control the pulse length to be greater than or equal to a first pulse length and less than a second pulse length, control the supply current value to have a third current density at a first time and a fourth current density at a second time.

Abstract: A transdermal permeant delivery system for delivery of at least one permeant into a tissue membrane of a subject comprises a filament array having a plurality of filaments that are disposed in a poration area and configured to deliver thermal energy to the tissue membrane to form a plurality of micropores; a applicator electrically connected to the filament array and configured to supply electrical energy to the filaments in order to create the plurality of micropores in the micropore area; and a patch configured for application on the micropore area and for releaseably containing at least one permeant. Method of treatment comprise using the transdermal permeant delivery system to administered a permeant in the form of a drug to a subject in need thereof.

Abstract: A transdermal delivery system for delivery of a triptan into a tissue membrane of a subject. The system includes a transdermal microporation apparatus for heating a skin surface and a triptan drug delivery patch. The drug delivery patch comprises a top layer comprising an adhesive, a middle layer comprising the triptan, and a bottom layer. A method for treating a subject comprises identifying a subject having a migraine, using the transdermal microporation apparatus to open a plurality of micropores in the skin of the subject, and applying the triptan drug delivery patch to the subject's skin over the micropores for a period of time effective to deliver the triptan through the micropores in an amount effective to treat the subject's migraine.

Abstract: An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R3 and R4 may together form a cyclic ring, and R1 and R2 independently represent an alkyl side chain having 1 to 16 carbon atoms.

Abstract: An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R3 and R4 may together form a cyclic ring, and R1 and R2 independently represent an alkyl side chain having 1 to 16 carbon atoms.

Abstract: An iontophoresis device activated in use, which is capable of supplying a dissolution liquid in an amount that depends on the amount of a drug when it is used, is provided. This iontophoresis device activated in use comprises: an absorber 11 formed of a material containing a dry drug 10 and capable of absorbing a liquid; a wall material 13 disposed around the absorber 11, having an adhesive layer 12 on the undersurface thereof; a support 15 disposed on the absorber 11 and the wall material 13, having an opening 14 in the central portion thereof; an electrode 25 disposed on the undersurface of the support 15; a diaphragm 20 disposed on the support 15; and a dissolution liquid reservoir 18 disposed on the diaphragm 20, retaining a dissolution liquid for dissolving the drug between the diaphragm 20 and itself, and having a protruding portion 17 for destroying the diaphragm 20 by pressing force.

Abstract: An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R3 and R4 may together form a cyclic ring, and R1 and R2 independently represent an alkyl side chain having 1 to 16 carbon atoms.

Abstract: Device structure 100 for iontophoresis provides electrode 101 and electrically conductive layer 102. Electrically conductive layer 102 contains active ingredient D and basic water swelling methacrylate copolymer P1 and/or acidic water swelling methacrylate copolymer P2. Electrode 101 and electrically conductive layer 102 are placed into a hollow of backing 103 and electrode terminal 104 is connected to electrode 101 through backing 103. Adhesive layer 105 is set around backing 103, and liner 106 to be removed when using the device, is placed so as to cover the hollow of backing 103.

Abstract: Device structure 100 for iontophoresis provides electrode 101 and electrically conductive layer 102. Electrically conductive layer 102 contains active ingredient D and basic water swelling methacrylate copolymer P1 and/or acidic water swelling methacrylate copolymer P2. Electrode 101 and electrically conductive layer 102 are placed into a hollow of backing 103 and electrode terminal 104 is connected to electrode 101 through backing 103. Adhesive layer 105 is set around backing 103, and liner 106 to be removed when using the device, is placed so as to cover the hollow of backing 103.

Abstract: An iontophoresis device activated in use, which is capable of supplying a dissolution liquid in an amount that depends on the amount of a drug when it is used, is provided. This iontophoresis device activated in use comprises: an absorber 11 formed of a material containing a dry drug 10 and capable of absorbing a liquid; a wall material 13 disposed around the absorber 11, having an adhesive layer 12 on the undersurface thereof; a support 15 disposed on the absorber 11 and the wall material 13, having an opening 14 in the central portion thereof; an electrode 25 disposed on the undersurface of the support 15; a diaphragm 20 disposed on the support 15; and a dissolution liquid reservoir 18 disposed on the diaphragm 20, retaining a dissolution liquid for dissolving the drug between the diaphragm 20 and itself, and having a protruding portion 17 for destroying the diaphragm 20 by pressing force.

Abstract: A device for iontophoresis that reduces irritation at the beginning of energization and efficiently supplies an amount of current required for drug administration in a predetermined length of time, is provided. With the device for iontophoresis, the oscillation frequency and duty cycle of a transistor 15 are adjusted at the beginning of energization, thereby controlling a back electromotive force developed across a coil 13 to gradually increase the output voltage. The microcomputer 12 controls the transistor 15 so as to receive signals from an output voltage detecting circuit that is formed of resistors 23 and 24 and an output current detecting circuit that is formed of resistors 25 and 26 and a capacitor 27, preventing an increasing of the output voltage when the detected output current reaches a limiting value, and preventing an increasing of the output current when the detected output voltage reaches a limiting value.

Abstract: It is intended to provide an interface for a transdermal drug administration device that can supply a drug almost evenly and favorably from a plurality of projections through skin. This interface for a transdermal drug administration device has a flat plate 8. The flat plate 8 comprises a plurality of two-dimensionally arranged conical or pyramidal projections 6 capable of piercing skin and a plurality of openings 7 capable of delivering a drug which are respectively arranged in correspondence with the projections. The openings 7 are respectively arranged in proximity to their corresponding projections 6. The flat plate 8 can be made of a metal or ceramics. The ratio between the number of the openings and the number of the projections can be 1:1 to 1:2.

Abstract: The invention provides a device for a percutaneous absorption preparation, provided with a solution storage container which can exhibit good solution migration independently of the level of force. The device for a percutaneous absorption preparation comprises an electrode film comprising a base member (1) and an electrode layer (2) and having a dissolution liquid passage hole (9), a drug impregnation member (3) mounted on the electrode layer (2) side of the electrode film, and a dissolution liquid storage container (5) bonded to the base member (1) side of the electrode film via a lid member (7) covering the solution passage hole (9). The dissolution liquid storage container (5) comprises a bottom and a sidewall. A protrusion (5b) which faces the dissolution liquid passage hole (9) is provided at the center of the bottom, and the sidewall is provided with a vertically folded part (5c).

Abstract: Device structure 100 for iontophoresis provides electrode 101 and electrically conductive layer 102. Electrically conductive layer 102 contains active ingredient D and basic water swelling methacrylate copolymer P1 and/or acidic water swelling methacrylate copolymer P2. Electrode 101 and electrically conductive layer 102 are placed into a hollow of backing 103 and electrode terminal 104 is connected to electrode 101 through backing 103. Adhesive layer 105 is set around backing 103, and liner 106 to be removed when using the device, is placed so as to cover the hollow of backing 103.

Abstract: The invention provides a device for a percutaneous absorption preparation, provided with a solution storage container which can exhibit good solution migration independently of the level of force. The device for a percutaneous absorption preparation comprises an electrode film comprising a base member (1) and an electrode layer (2) and having a dissolution liquid passage hole (9), a drug impregnation member (3) mounted on the electrode layer (2) side of the electrode film, and a dissolution liquid storage container (5) bonded to the base member (1) side of the electrode film via a lid member (7) covering the solution passage hole (9). The dissolution liquid storage container (5) comprises a bottom and a sidewall. A protrusion (5b) which faces the dissolution liquid passage hole (9) is provided at the center of the bottom, and the sidewall is provided with a vertically folded part (5c).

Abstract: To provide an easily producible mass-production type iontophoresis device having a structure that a dissolution liquid-storing container is integrated with an iontophoresis electrode, a dissolution liquid and a drug can be mixed by simple operations, and it is free from a risk of leakage of electricity. The device comprises an electrode film having an electrode layer (2) formed on a base (1), a drug-loaded member (3) arranged on the electrode-layer-forming side of the electrode film, and a dissolution liquid-storing container (5) arranged on the non-electrode-layer-forming side of the electrode film, wherein the electrode film is provided with a dissolution liquid passing hole (9), a flange (5a) of the dissolution liquid-storing container (5) is bonded to the electrode film via an aluminum lid member (7) which covers the dissolution liquid passing hole (9), and the aluminum lid member (7) is arranged within the flange outer diameter of the dissolution liquid-storing container.